Rafael Holdings Inc (RFL)

$1.24 -0.05 (-3.88%)
Market Cap 66.27M
Revenue (ttm) 920,000.00
Net Income (ttm) -30.52M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3,317.39%
Debt to Equity Ratio 0.01
Volume 62,900
Avg Vol 86,950
Day's Range N/A - N/A
Shares Out 51.77M
Stochastic %K 0%
Beta 0.58
Analysts Strong Buy
Price Target N/A

Company Profile

Rafael Holdings, Inc. primarily engages in holding interests in clinical and early-stage pharmaceutical companies, and medical devices in the United States and Israel. It operates in three segments, Healthcare, Infusion Technology, and Real Estate. The company engages in the development and commercialization of therapies that exploit the metabolic differences between normal cells and cancer cells. Its lead drug candidate is Trappsol Cyclo, which is in phase 3 clinical trial being evaluated for t...

Industry: Real Estate Services
Sector: Real Estate
Phone: 212 658 1450
Address:
520 Broad Street, Newark, United States
PenkeInvesting
PenkeInvesting Mar. 20 at 12:13 AM
Fundamental analysis of $RFL (Rafael Holdings, Inc.) based on financial data and reported results. #RFL #Rafael
0 · Reply
ReposedAnchor
ReposedAnchor Mar. 17 at 5:53 PM
$RFL
0 · Reply
GDS_investing
GDS_investing Mar. 17 at 4:46 PM
$RFL “We remain pleased with the progress of our pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, which the Data Monitoring Committee (DMC) recommended continuing after their review of prespecified safety and efficacy data at 48 weeks. We believe that Trappsol® Cyclo™ could provide an important new treatment option for patients suffering from this rare and fatal genetic disease,” said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings.
1 · Reply
GDS_investing
GDS_investing Mar. 17 at 4:46 PM
$RFL “We are on track to complete this 96-week Phase 3 clinical trial, the largest ever conducted in this indication, and report preliminary top line results in the third quarter of this calendar year,” said Joshua Fine, Chief Operating Officer of Rafael Holdings.
0 · Reply
GDS_investing
GDS_investing Mar. 17 at 4:26 PM
$RFL
0 · Reply
jujusmithstockster
jujusmithstockster Mar. 17 at 3:22 PM
$RFL this would have to reach $30 doll haira before i ever recoup my losses from merger... anyone in here think that's EVER possible lol
1 · Reply
Moksi
Moksi Mar. 17 at 6:22 AM
$RFL
0 · Reply
Pizzino
Pizzino Mar. 16 at 9:39 PM
$RFL
0 · Reply
CaseOfTheYips1
CaseOfTheYips1 Mar. 16 at 9:19 PM
$RFL what is the world did they spend $12M in R&D? Zero news on that one Joshua… ya fired
0 · Reply
CaseOfTheYips1
CaseOfTheYips1 Mar. 16 at 8:24 PM
$RFL 3rd quarter readout 🤦🏻‍♂️… as late as September… fml
1 · Reply
Latest News on RFL
Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

Mar 16, 2026, 4:01 PM EDT - 4 days ago

Rafael Holdings Reports Second Quarter Fiscal 2026 Financial Results

Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

Dec 11, 2025, 4:01 PM EST - 3 months ago

Rafael Holdings Reports First Quarter Fiscal 2026 Financial Results

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

Oct 29, 2025, 4:24 PM EDT - 5 months ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2025 Financial Results

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

Oct 28, 2025, 4:01 PM EDT - 5 months ago

Rafael Holdings Mourns the Passing of Lead Independent Director, Stephen Greenberg, and Announces the Appointment of Alan Grayson to its Board of Directors

Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

Sep 16, 2025, 8:00 AM EDT - 6 months ago

Rafael Holdings Announces Presentation of Preliminary Data from Ongoing Phase 3 TransportNPC™ Open-Label, Single-Arm Sub-Study in Patients Less Than 3 Years Old

Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

Aug 27, 2025, 8:00 AM EDT - 7 months ago

Rafael Holdings Announces Abstracts Accepted for Oral and Poster Presentations at the 15th International Congress of Inborn Errors of Metabolism (ICIEM)

Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

Jun 11, 2025, 7:00 AM EDT - 10 months ago

Rafael Holdings Reports Third Quarter Fiscal 2025 Financial Results

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

Jun 4, 2025, 4:01 PM EDT - 10 months ago

Rafael Holdings, Inc. Announces Final Results and Closing of Rights Offering

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

May 20, 2025, 4:01 PM EDT - 10 months ago

Rafael Holdings, Inc. Provides Update to the Description of Subscription Rights Related to its Public Warrants in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

May 5, 2025, 7:00 AM EDT - 11 months ago

Rafael Holdings, Inc. Announces Revised Subscription Rights in Connection With its Previously Announced $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Apr 29, 2025, 4:30 PM EDT - 11 months ago

Rafael Holdings, Inc. Announces Proposed Terms of a $25 Million Rights Offering to Support Its Commitment to the Development and Potential Launch of Trappsol® Cyclo™

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

Apr 24, 2025, 4:15 PM EDT - 11 months ago

Rafael Holdings Strengthens its Focus on the Development of Trappsol® Cyclo™ and Announces Chief Executive Officer Bill Conkling Will Be Stepping Down from His Role

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Mar 26, 2025, 6:50 AM EDT - 1 year ago

Rafael Holdings Completes Merger with Cyclo Therapeutics Following Shareholder Approvals

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

Mar 13, 2025, 5:50 PM EDT - 1 year ago

Rafael Holdings Reports Second Quarter Fiscal 2025 Financial Results

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

Feb 20, 2025, 4:35 PM EST - 1 year ago

CYCLO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Cyclo Therapeutics, Inc. - CYTH

CYTH

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

Dec 11, 2024, 7:00 AM EST - 1 year ago

Rafael Holdings Reports First Quarter Fiscal 2025 Financial Results

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

Nov 6, 2024, 7:14 PM EST - 1 year ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2024 Financial Results

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTX and RFL on Behalf of Shareholders

Oct 2, 2024, 12:00 PM EDT - 1 year ago

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates MNTX and RFL on Behalf of Shareholders

MNTX

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

Aug 22, 2024, 10:19 AM EDT - 1 year ago

Accession Risk Management Group Closes $1 Billion Financing to Further Accelerate Growth of Risk Strategies and One80 Intermediaries

CYTH

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

Aug 22, 2024, 6:50 AM EDT - 1 year ago

Rafael Holdings and Cyclo Therapeutics Enter Into a Definitive Merger Agreement

CYTH

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Aug 22, 2024, 6:50 AM EDT - 1 year ago

Rafael Holdings and Cyclo Therapeutics Enter into a Definitive Merger Agreement

Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

Jun 14, 2024, 4:01 PM EDT - 1 year ago

Rafael Holdings Reports Third Quarter Fiscal 2024 Financial Results

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Mar 13, 2024, 5:04 PM EDT - 2 years ago

Rafael Holdings Reports Second Quarter Fiscal 2024 Financial Results

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Dec 14, 2023, 4:01 PM EST - 2 years ago

Rafael Holdings Reports First Quarter Fiscal 2024 Financial Results

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

Oct 30, 2023, 4:01 PM EDT - 2 years ago

Rafael Holdings Reports Fourth Quarter and Full Year Fiscal 2023 Financial Results

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

Aug 2, 2023, 8:16 AM EDT - 2 years ago

Cyclo Therapeutics Announces Closing of $5.0 Million Private Placement with Rafael Holdings, Inc.

CYTH

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

Jun 13, 2023, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Third Quarter Fiscal 2023 Financial Results and Provides Business Update

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

Jun 5, 2023, 8:05 AM EDT - 3 years ago

Cyclo Therapeutics Announces Execution of Definitive Agreement with Rafael Holdings, Inc. Providing for $5.0 Million of Additional Funding Via a Private Placement

CYTH

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

May 2, 2023, 8:12 AM EDT - 3 years ago

Cyclo Therapeutics Announces Closing of Strategic Investment Through a $2.1 Million Private Placement from Rafael Holdings, Inc. (NYSE:RFL)

CYTH

Rafael Holdings Announces up to $5 Million Share Repurchase Program

Apr 4, 2023, 8:00 AM EDT - 3 years ago

Rafael Holdings Announces up to $5 Million Share Repurchase Program

Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results

Mar 14, 2023, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Second Quarter Fiscal 2023 Financial Results

Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results

Dec 13, 2022, 7:00 AM EST - 3 years ago

Rafael Holdings Reports First Quarter Fiscal 2023 Financial Results

Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities

Nov 15, 2022, 4:01 PM EST - 3 years ago

Rafael Holdings to Focus on Strategic Business Development Initiatives and Curtail Early Stage Development Activities

Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results

Oct 31, 2022, 4:01 PM EDT - 3 years ago

Rafael Holdings Reports Fourth Quarter Fiscal 2022 Financial Results

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

Sep 28, 2022, 7:00 AM EDT - 3 years ago

Cornerstone Pharmaceuticals Initiates Phase 1 Trial of CPI-613® (devimistat) in Combination with Chemoradiation for the Treatment of Advanced Pancreatic Cancer

Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage

Aug 23, 2022, 7:43 AM EDT - 3 years ago

Rafael Holdings Sells its Building Located at 520 Broad Street in Newark, New Jersey and Associated 800-Car Public Garage

Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

Jul 6, 2022, 8:00 AM EDT - 4 years ago

Cornerstone Pharmaceuticals Strengthens Scientific Advisory Board with the Appointment of Distinguished Scholar Jason Locasale, Ph.D.

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE

Jun 16, 2022, 2:14 PM EDT - 4 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism – UPDATE

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

Jun 16, 2022, 8:00 AM EDT - 4 years ago

Cornerstone Pharmaceuticals Announces Published Data on CPI-613® (Devimistat) as an Effective Approach to Targeting Carcinoma Catabolism

Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results

Jun 14, 2022, 4:01 PM EDT - 4 years ago

Rafael Holdings Reports Third Quarter Fiscal 2022 Financial Results

Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Jun 1, 2022, 8:00 AM EDT - 4 years ago

Cornerstone Pharmaceuticals to Present Pancreatic Cancer, Clear Cell Sarcoma and Biliary Tract Cancer Research Featuring CPI-613® (Devimistat) at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals' CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer

May 24, 2022, 11:04 AM EDT - 4 years ago

European Medicines Agency Grants Orphan Drug Designation to Cornerstone Pharmaceuticals' CPI-613® (Devimistat) for Treatment of Patients with Advanced Unresectable Biliary Tract Cancer

Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results

Mar 17, 2022, 4:01 PM EDT - 4 years ago

Rafael Holdings Reports Second Quarter Fiscal 2022 Financial Results

The Law Offices of Frank R. Cruz Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 11, 2022, 4:00 PM EST - 4 years ago

The Law Offices of Frank R. Cruz Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 10, 2022, 2:00 PM EST - 4 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Its Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

Mar 7, 2022, 7:00 PM EST - 4 years ago

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Rafael Holdings, Inc. (RFL) on Behalf of Investors

PenkeInvesting
PenkeInvesting Mar. 20 at 12:13 AM
Fundamental analysis of $RFL (Rafael Holdings, Inc.) based on financial data and reported results. #RFL #Rafael
0 · Reply
ReposedAnchor
ReposedAnchor Mar. 17 at 5:53 PM
$RFL
0 · Reply
GDS_investing
GDS_investing Mar. 17 at 4:46 PM
$RFL “We remain pleased with the progress of our pivotal Phase 3 TransportNPC™ study evaluating Trappsol® Cyclo™ for the treatment of Niemann-Pick Disease Type C1, which the Data Monitoring Committee (DMC) recommended continuing after their review of prespecified safety and efficacy data at 48 weeks. We believe that Trappsol® Cyclo™ could provide an important new treatment option for patients suffering from this rare and fatal genetic disease,” said Howard Jonas, Chief Executive Officer, Executive Chairman and Chairman of the Board of Rafael Holdings.
1 · Reply
GDS_investing
GDS_investing Mar. 17 at 4:46 PM
$RFL “We are on track to complete this 96-week Phase 3 clinical trial, the largest ever conducted in this indication, and report preliminary top line results in the third quarter of this calendar year,” said Joshua Fine, Chief Operating Officer of Rafael Holdings.
0 · Reply
GDS_investing
GDS_investing Mar. 17 at 4:26 PM
$RFL
0 · Reply
jujusmithstockster
jujusmithstockster Mar. 17 at 3:22 PM
$RFL this would have to reach $30 doll haira before i ever recoup my losses from merger... anyone in here think that's EVER possible lol
1 · Reply
Moksi
Moksi Mar. 17 at 6:22 AM
$RFL
0 · Reply
Pizzino
Pizzino Mar. 16 at 9:39 PM
$RFL
0 · Reply
CaseOfTheYips1
CaseOfTheYips1 Mar. 16 at 9:19 PM
$RFL what is the world did they spend $12M in R&D? Zero news on that one Joshua… ya fired
0 · Reply
CaseOfTheYips1
CaseOfTheYips1 Mar. 16 at 8:24 PM
$RFL 3rd quarter readout 🤦🏻‍♂️… as late as September… fml
1 · Reply
LC_Investor
LC_Investor Mar. 16 at 8:21 PM
$RFL https://rafaelholdings.irpass.com/profiles/investor/NewsPrint.asp?b=2323&ID=163273&m=rl&v=2&g=1063
1 · Reply
Pizzino
Pizzino Mar. 14 at 10:36 AM
$RFL from a bit of research it looks like the Wit tnbc connection is a dead end. According to the university’s ai, Wits it going at it alone.
1 · Reply
Pizzino
Pizzino Mar. 13 at 10:57 PM
$RFL this is obviously talking about us…. they plan to start trials and could be done in as little as 3 years. I wonder if we are waiting on the PRV to fund this. https://wits-enterprise.co.za/a/wits-develops-a-therapeutic-for-aggressive-breast-cancer
1 · Reply
Fashtrades
Fashtrades Mar. 13 at 10:35 PM
$RFL @fisher04
0 · Reply
Pizzino
Pizzino Mar. 13 at 9:54 PM
$RFL
1 · Reply
fisher04
fisher04 Mar. 13 at 8:35 PM
$RFL When is data readout ? all reponses will be much appreciated.
1 · Reply
marinax
marinax Mar. 13 at 8:07 PM
$RFL stuck here from last 3 years . average is 9$ . down 65k . anyone buying or average down ?
1 · Reply
Fashtrades
Fashtrades Mar. 13 at 6:47 PM
$RFL WHY THE DROP ?? 😳😳
1 · Reply
sg44
sg44 Mar. 12 at 3:54 PM
$RFL Gemini wow!
2 · Reply
Moksi
Moksi Mar. 12 at 4:54 AM
$RFL
0 · Reply
Love_To_Learn
Love_To_Learn Mar. 10 at 5:45 PM
$RFL MADE A CHANGE TO U
1 · Reply
sg44
sg44 Mar. 10 at 5:18 PM
$RFL today at $11 ZVRA has a market cap of more than $730 M on a diluted basis. Should we not get some of that love from investors. After all Trappsol Cyclo is the biggest pipeline threat to Mypliffa.
2 · Reply